Adherence in Chronic Myeloid Leukemia (CML

12/6/2014

Blood Journal | Studying the Impact of Imatinib Mesylate (IM) Adherence in Chronic Myeloid Leukemia (CML) patients’ Responses in the State of Qatar

Studying the Impact of Imatinib Mesylate (IM) Adherence in Chronic Myeloid Leukemia (CML) patients’ Responses in the State of Qatar Nader I AlDewik, BSc, MSc, PhD1, Hisham Morsi, PhD DSc, MBBCH, MD2, Rola Ghasoub, BSc*,3, and Mohamed A. Yassin, MBBS ,MSc,CABM,FACP4 Author Affiliations

Article

Info & Metrics

ELetters

Abstract Background: The introduction of Imatinib Mesylate (IM) has revolutionized the outcome of Chronic Myeloid Leukemia (CML) patients. However, the success of the rationally designed therapy is tempered by the understanding that a substantial proportion of CML patients fail treatment. In Qatar, 54% of CML patients do fail IM according to European leukemia net (ELN) recommendations 2013. Point mutation & unique tri-nucleotide insertions explained only 14% of treatment failure. Additional chromosomal abnormalities were the most common cause of IM failure in our patients’ cohort & were documented in 50% of cases. 14% of patients stopped IM due to intolerance & the mechanisms of resistance remained unknown in 28% of patients. Other cause such as patients’ adherence to IM is being prospectively investigated. Therefore, Non adherence to IM must be ruled out as a possible cause of lack of optimal response before considering such patients to be IMresistant & switching them to next-line treatment. Aim: data:text/html;ch…

1/3

12/6/2014


To correlate between CML patients’ adherence to IM treatment & their responses and identify the factors affecting non-adherence. Methods: 36 CML patients (5 citizens & 31 residents) are consented into the study. adherence to Imatinib was assessed using four different techniques: calculation of the Medication Possession Ratio (MPR), electronic Medical Records (eMR), survey questionnaire & Medication Event Monitoring System (MEMS). MPR is defined as the sum of the days' supply of medication divided by the number of days between the first fill & the last refill. Patients medications history was obtained from questionnaire, pharmacy electronic Medical record (eMR) & studying drug – drug interactions was done using MICROMEDEX® 1.0 (Healthcare Series). The Questionnaire used to identify potential factors revolving around the patient's lifestyle, affordability & knowledge related to IM, in addition to standardized evaluation based on the 9-item Morisky Medication Adherence Scale (MMAS) ranging from 1 to 13. Scores ≤10 indicates non adherence whereas ≥ 11 indicates adherence. Patient adherence was tracked electronically using the Medication Electronic Monitoring System (MEMS) that provided real time measures of adherence for a period up to 4 months. 95 Peripheral blood (PB) samples were collected & the level of BCRABL1transcripts was measured via RT-QPCR. The ELN 2013 recommendations for the management of CML was adopted & employed in this study to assess the response/resistance of patients to treatment. Responses were defined at the haematological, cytogenetic & molecular levels. Patients responses were classified into optimal, suboptimal or failure. Results: Out of 36 patients, 23 patients were adherent (MMAS, MPR &MEMS were ≥ data:text/html;ch…

2/3

12/6/2014


80%) & 13 patients were classified as non-adherent (MMAS, MPR &MEMS were